Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited furnished a Form 6-K announcing that it has attached an Australian Securities Exchange notice titled “Proposed issue of securities - IMC.” The filing provides the ASX public notice as Exhibit 99.1 for U.S. investors’ awareness.
The submission is an information update and does not include financial results or transaction terms. It primarily serves to make the ASX announcement available to the U.S. market.
Immuron Limited (IMRN) furnished a Form 6-K announcing it has attached an Australian Securities Exchange notice as Exhibit 99.1. The exhibit is titled “IMM-529 IND approved by FDA”, indicating the company reported an FDA approval of an Investigational New Drug for IMM-529. The ASX announcement was published on November 5, 2025.
The report states it is being furnished, not filed, under the Exchange Act and will not be incorporated by reference into other filings except where expressly referenced.
Immuron Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to an announcement it released on the Australian Securities Exchange. The filing states that the company published a public notice on October 31, 2025 titled “Clinical Trial Update”, and that this announcement is attached to the Form 6-K as Exhibit 99.1. The company also clarifies that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will not be incorporated into other Securities Act filings unless specifically referenced.
Immuron Limited submitted a Form 6-K to provide U.S. investors with an announcement it released on the Australian Securities Exchange. The attached notice is titled “Immuron launch PROIBS for IBS,” indicating the company has announced the launch of a product called PROIBS aimed at irritable bowel syndrome (IBS). The Form 6-K simply furnishes this ASX announcement as an exhibit and states that it is not deemed filed under the Exchange Act nor automatically incorporated by reference into other U.S. securities filings.
Immuron Limited furnished a Form 6-K to provide investors with an Australian Securities Exchange announcement dated October 21, 2025. The filing attaches Exhibit 99.1 titled “Presentation to AusBiotech Invest 2025 Conference.”
The material is furnished, not filed, under the Exchange Act and is not incorporated by reference into other securities filings unless specifically referenced. This update primarily shares the presentation made available to the market.
Immuron Limited furnished a Form 6‑K that attaches two Australian Securities Exchange announcements. The notices, dated October 20, 2025, are titled “Application for quotation of securities - IMC” and “Cleansing Notice.”
The company states this Form 6‑K, including the exhibits, is being furnished and is not deemed “filed” under the Exchange Act, and it is not incorporated by reference into other filings unless expressly referenced.
FAQ
What is the current stock price of Immuron (IMRN)?
What is the market cap of Immuron (IMRN)?
